COLUMBIA, Md.--(BUSINESS WIRE)--CELSION CORPORATION (AMEX: CLN) today announced that, in conjunction with its Phase III Primary Liver Cancer protocol submission under the SPA Guidance, the Food and Drug Administration (FDA) has requested an update to the study’s Radiology Charter. The company provided the updated document to the Agency on the date of the request, September 19, 2007.
